ROCK2 inhibition: A futuristic approach for the management of Alzheimer's disease

Mani S 1 , Jindal D 2 , Chopra H 3 , Jha SK 4 , Singh SK 5 , Ashraf GM 6 Show all authors , Kamal M 7 , Iqbal D 8 , Chellappan DK 9 , Dey A 10 , Dewanjee S 11 , Singh KK 12 , Ojha S 13 , Singh I 3 , Gautam RK 14 , Jha NK 15

Affiliations 

  • 1 Centre for Emerging Disease, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, UP, India. Electronic address: [email protected]
  • 2 Centre for Emerging Disease, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, UP, India
  • 3 Chitkara College of Pharmacy, Chitkara University, Punjab, India
  • 4 Department of Biotechnology, School of Engineering and Technology (SET), Sharda University, Greater Noida, Uttar Pradesh 201310, India; Department of Biotechnology, School of Applied & Life Sciences (SALS), Uttaranchal University, Dehradun 248007, India; Department of Biotechnology Engineering and Food Technology, Chandigarh University, Mohali 140413, India
  • 5 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India
  • 6 Department of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, University City, Sharjah 27272, United Arab Emirates
  • 7 Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
  • 8 Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11952, Saudi Arabia
  • 9 Department of Life Sciences, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia
  • 10 Department of Life Sciences, Presidency University, 86/1 College Street, Kolkata 700073, India
  • 11 Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
  • 12 Department of Genetics, UAB School of Medicine, The University of Alabama at Birmingham, United States
  • 13 Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, PO box 15551 Al Ain, Abu Dhabi, United Arab Emirates
  • 14 Department of Pharmacology, Indore Institute of Pharmacy, Indore, 453331, India. Electronic address: [email protected]
  • 15 Department of Biotechnology, School of Engineering and Technology (SET), Sharda University, Greater Noida, Uttar Pradesh 201310, India; Department of Biotechnology, School of Applied & Life Sciences (SALS), Uttaranchal University, Dehradun 248007, India; Department of Biotechnology Engineering and Food Technology, Chandigarh University, Mohali 140413, India. Electronic address: [email protected]
Neurosci Biobehav Rev, 2022 11;142:104871.
PMID: 36122738 DOI: 10.1016/j.neubiorev.2022.104871

Abstract

Neurons depend on mitochondrial functions for membrane excitability, neurotransmission, and plasticity. Mitochondrial dynamics are important for neural cell maintenance. To maintain mitochondrial homeostasis, lysosomes remove dysfunctional mitochondria through mitophagy. Mitophagy promotes mitochondrial turnover and prevents the accumulation of dysfunctional mitochondria. In many neurodegenerative diseases (NDDs), including Alzheimer's disease (AD), mitophagy is disrupted in neurons. Mitophagy is regulated by several proteins; recently, Rho-associated coiled-coil containing protein kinase 2 (ROCK2) has been suggested to negatively regulate the Parkin-dependent mitophagy pathway. Thus, ROCK2 inhibition may be a promising therapy for NDDs. This review summarizes the mitophagy pathway, the role of ROCK2 in Parkin-dependent mitophagy regulation, and mitophagy impairment in the pathology of AD. We further discuss different ROCK inhibitors (synthetic drugs, natural compounds, and gene therapy-based approaches) and examine their effects on triggering neuronal growth and neuroprotection in AD and other NDDs. This comprehensive overview of the role of ROCK in mitophagy inhibition provides a possible explanation for the significance of ROCK inhibitors in the therapeutic management of AD and other NDDs.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications